Multi-parameter metabolic vulnerability index evaluations
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and systems to determine a subject's metabolic vulnerability index (MVX) score using at least one defined mathematical model of risk. The methods comprise evaluating various biomarkers to distinguish various health risks. In one embodiment, the method comprises evaluating biomarkers to determine a relative risk of premature all-cause mortality. The model may include NMR-derived measurements of GlycA, S-HDLP, branched chain amino acids (BCAAs), ketone bodies, total serum protein, and citrate in at least one biosample of the subject.
Claims24
A method of determining the levels of markers associated with a subject's relative risk of premature death comprising:
- obtaining a sample from the subject;
- and
- measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody).
(canceled)
16-22. (canceled)
A system comprising:
- an NMR spectrometer configured to acquire an NMR spectrum and/or spectra comprising at least one signal for GlycA, at least one signal for at least one high density lipoprotein particle (HDLP) subclass, at least one signal for at least one branched chain amino acid (BCAA), and at least one signal for at least one ketone body (KetoneBody);
- and
- a processor to determine a metabolic vulnerability index (MVX) value based on the measured at least one signal for the GlycA, the at least one high density lipoprotein particle (HDLP) subclass, the at least one branched chain amino acid (BCAA), and the at least one ketone body (KetoneBody)
- wherein the processor comprises or communicates with a memory.
(canceled)
A method of monitoring a patient comprising:
- (a) obtaining a sample from the subject;
- (b) measuring GlycA, at least one high density lipoprotein particle (HDLP) subclass, at least one branched chain amino acid (BCAA), and at least one ketone body (KetoneBody) and optionally at least one of citrate (Citrate) and serum protein (Protein) in the sample;
- (c) determining a metabolic vulnerability index (MVX) value based on the measurements;
- (d) repeating steps (a)-(c) at a later time point;
- and
- (e) evaluating at least whether the MVX value has increased or decreased over time.
30-31. (canceled)
Dependencies are inferred from the claim text.